Education
About Us
Working with TipRanks
Follow Us
Rapport Therapeutics, Inc. (RAPP)
:RAPP
RAPP Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.43 - $42.27
Previous CloseN/A
Volume10.11K
Average Volume (3M)1.21M
Market Cap
$1.23B
Enterprise Value$154.32M
Total Cash (Recent Filing)$260.45M
Total Debt (Recent Filing)$11.86M
Price to Earnings (P/E)―
Beta1.64
Next Earnings
Nov 06, 2025EPS Estimate
-0.78Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.75
Shares Outstanding46,113,304
10 Day Avg. Volume882,791
30 Day Avg. Volume1,211,376
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.13
Enterprise Value/Revenue214.33
Enterprise Value/Gross Profit-1.13K
Enterprise Value/Ebitda-1.52
Forecast
1Y Price Target
$52.00Price Target Upside95.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsRapport Therapeutics announced positive topline results from the Phase IIa trial of RAP-219 in focal seizures.
Drug EfficacyRAP-219 surpasses expectations with a 71% reduction in LE and 78% reduction in clinical seizures, providing strong evidence of its potential to become a mainstay in the treatment of FOS.
TolerabilityThe tolerability profile of RAP-219 looks good with no evidence of aggression or irritability, addressing concerns seen with other treatments like Fycompa.
Bears Say
Adverse EffectsDr. Anschel expressed concern about the potential impact of RAP-219 on memory and will be monitoring for this adverse effect as more clinical data accrues.
Steady State ConcernsDr. Anschel noted a potential concern with the 8-14 day half-life of RAP-219, as it may take a long time to reach a steady state.
Rapport Therapeutics, Inc. News
RAPP FAQ
What was Rapport Therapeutics, Inc.’s price range in the past 12 months?
Rapport Therapeutics, Inc. lowest stock price was $6.43 and its highest was $42.27 in the past 12 months.
What is Rapport Therapeutics, Inc.’s market cap?
Rapport Therapeutics, Inc.’s market cap is $1.23B.
When is Rapport Therapeutics, Inc.’s upcoming earnings report date?
Rapport Therapeutics, Inc.’s upcoming earnings report date is Nov 06, 2025 which is in 39 days.
How were Rapport Therapeutics, Inc.’s earnings last quarter?
Rapport Therapeutics, Inc. released its earnings results on Aug 07, 2025. The company reported -$0.75 earnings per share for the quarter, beating the consensus estimate of -$0.814 by $0.064.
Is Rapport Therapeutics, Inc. overvalued?
According to Wall Street analysts Rapport Therapeutics, Inc.’s price is currently Undervalued.
Does Rapport Therapeutics, Inc. pay dividends?
Rapport Therapeutics, Inc. does not currently pay dividends.
What is Rapport Therapeutics, Inc.’s EPS estimate?
Rapport Therapeutics, Inc.’s EPS estimate is -0.78.
How many shares outstanding does Rapport Therapeutics, Inc. have?
Rapport Therapeutics, Inc. has 46,113,304 shares outstanding.
What happened to Rapport Therapeutics, Inc.’s price movement after its last earnings report?
Rapport Therapeutics, Inc. reported an EPS of -$0.75 in its last earnings report, beating expectations of -$0.814. Following the earnings report the stock price went up 5.476%.
Which hedge fund is a major shareholder of Rapport Therapeutics, Inc.?
Currently, no hedge funds are holding shares in RAPP
Rapport Therapeutics, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$52.00 (95.56% Upside)
$52.00 (95.56% Upside)
Blogger Sentiment
Bullish
RAPP Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 684.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.6M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
29.51%
12-Months-Change
Fundamentals
Return on Equity
-29.42%
Trailing 12-Months
Asset Growth
-17.51%
Trailing 12-Months
Company Description
Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc. (RAPP) is a biotechnology company focused on developing precision medicines to treat neurological disorders. By leveraging advanced drug discovery techniques, the company aims to create targeted therapies that address specific neural pathways associated with various conditions. Rapport Therapeutics operates in the biopharmaceutical sector, with a core emphasis on innovative research and development in neuroscience.
RAPP Stock 12 Month Forecast
Average Price Target
$52.00
▲(95.56% Upside)
Technical Analysis
Ownership Overview
7.17% Insiders
24.17% Mutual Funds
0.03% Other Institutional Investors
63.22% Public Companies and
Individual Investors